#None #VXM01 #Vaximm AG #BCM Europe

Vaximm AG Enters Licensing Agreement with BCM Europe

In a strategic move to accelerate its cancer immunotherapy developments, Vaximm AG, a subsidiary of OSR Holdings, has signed a non-binding term sheet with BCM Europe AG. This Swiss-based life sciences investment group, which also stands as OSR’s largest shareholder, aims to explore an exclusive global licensing deal for VXM01, Vaximm’s innovative oral cancer immunotherapy platform.

Overview of the Term Sheet

The term sheet establishes a six-month exclusivity period during which both parties intend to negotiate a definitive licensing agreement. This will include a $20 million upfront payment to Vaximm, alongside potential milestone payments that could total up to $815 million through clinical, regulatory, and commercial stages. Furthermore, Vaximm retains its ownership of the intellectual property surrounding VXM01, allowing them to proceed with their mission without relinquishing control.

Strategic Financing Model

The cooperation between Vaximm and BCM Europe is modeled after successful financial strategies seen in entities like Royalty Pharma and Blackstone Life Sciences. By acting as a financial intermediary, BCM Europe will provide the necessary funding for the development and partnering required to secure a global out-license with a major pharmaceutical company, thereby potentially enabling a wide-reaching commercial future for VXM01.

Statements from Leadership

Andreas Niethammer, Vaximm's incoming CEO, emphasized the importance of this collaboration, stating, "This term sheet marks an important step forward for Vaximm and our VXM01 oral T-cell immunotherapy platform." He expressed optimism that the partnership with BCM Europe would expedite both the development and global market entry of VXM01, aiding their overall goals in delivering innovative treatments.

Tim Smith, Head of Investor Relations for OSR Holdings, echoed similar sentiments, noting that Vaximm's strategy to explore the global opportunity reflects shared aspirations with BCM Europe. The commitment to finalize an arrangement that positions VXM01 for future partnerships with larger pharmaceutical firms is evidently a priority for both parties.

Innovative Aspects of VXM01

VXM01 is designed to leverage an oral T-cell platform that utilizes live, attenuated bacterial vectors to induce strong immune responses against tumors. Its approach represents a significant advancement in oncology treatments, with promise for various cancer indications given its demonstrated safety and effectiveness in clinical settings. This innovative method of treatment could revolutionize how patients approach cancer therapy.

A Forward-Looking Perspective

A unique aspect of the deal is the inclusion of a blockchain-based royalty participation mechanism. This innovative feature uses “TAC” tokens as a representation of future royalty income from VXM01, which could potentially attract further investment and broaden the scope of profit-sharing within participating stakeholders. This tokenization could grant early investors access to ongoing revenues from successful commercialization efforts.

During the exclusivity period, both Vaximm and BCM Europe will be collaborating extensively to finalize their arrangements. This involves completing due diligence, preparing necessary materials for potential partners, and meticulously structuring the licensing documentation.

In summary, Vaximm AG’s partnership with BCM Europe is a strategic maneuver that not only secures immediate financial support but also paves the way for future collaborations, paving the way for groundbreaking advancements in cancer therapy.

About Vaximm AG and Its Parent Company

Vaximm AG operates as a biotech firm based in Switzerland and is part of OSR Holdings. OSR Holdings Inc. is listed on NASDAQ under the ticker OSRH, focusing on advancements in healthcare and wellness through various listed developments, including immuno-oncology and regenerative biologics. Vaximm continues to push the boundaries of cancer treatment through its revolutionary immunotherapies designed to improve patient outcomes across diverse cancer types.